- ALOT Dashboard
- Financials
- Filings
-
Holdings
- Transcripts
- ETFs
- Insider
- Institutional
- Shorts
-
8-K Filing
AstroNova (ALOT) 8-KRegulation FD Disclosure
Filed: 12 Jan 06, 12:00am
![]() Participating: Participating: Albert W. Ondis, Astro-Med Chairman & CEO Albert W. Ondis, Astro-Med Chairman & CEO Everett V. Pizzuti, Astro-Med President & COO Everett V. Pizzuti, Astro-Med President & COO Joseph P. O’Connell, Astro-Med Vice President & CFO The Eighth Annual The Eighth Annual Needham Growth Conference Needham Growth Conference January 10-13, 2006 January 10-13, 2006 Astro-Med, Inc Astro-Med, Inc Presentation to Presentation to Exhibit 99.1 |
![]() Forward-Looking Statements Certain of the statements contained in this presentation may be considered forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Act of 1934, as amended. To the extent that any of the statements contained herein relating to Astro-Med, Inc. or its products or markets are forward-looking, such statements are based on management’s assumptions and/or current expectations that involve a number of uncertainties and risks. Such uncertainties and risks include, but are not limited to, those outlined in our Form 10K and other public filings, which we make from time to time with the Securities and Exchange Commission. |
![]() Meet (ALOT) |
![]() Meet Astro-Med’s QuickLabel Systems Product Group |
![]() Product Overview Product Overview Label Printers Printing Supplies |
![]() Major QuickLabel Opportunity: Digital Color Label Printers |
![]() Products Requiring Custom Printed Labels • Foods and Beverages • Cosmetics • Nutraceuticals and Pharmaceuticals • Chemicals: Agricultural and Cleansers • Advertising Novelties • Biomedical Devices • Tires |
![]() Why Companies Buy QuickLabel Printers: Why Companies Buy QuickLabel Printers: 100% Packaging Accuracy, as required by law in biomedical and pharmaceutical industries. Labels printed in late-stage production on-demand improve accuracy. Prototype Packaging of products for diverse domestic and foreign market distribution channels. Custom Private Labels and Store-Brand Labels to create higher profit margin opportunities in many retail and wholesale market segments. |
![]() |
![]() New in FY2007 Photo-Quality Digital Label Printer |
![]() New Vivo! Photo- Quality Label Printer – 600 dpi QLS-4100 Xe Label Printer – 300 dpi |
![]() QuickLabel Outlook • Current Annual Revenue Rate: $30 million (50%) • Fiscal Year 2007: Significant Growth from new product sales |
![]() Meet Astro-Med’s Test & Measurement Product Group |
![]() Product Overview Digital Data Acquisition Systems & Consumables Specialty Printer Systems & Consumables |
![]() Test & Measurement Product Group • Aerospace Systems • Power Generation & Transmission Systems • Paper and Metal Mill Systems • Automotive Production Systems Market Applications: |
![]() Notable T&M Customers: |
![]() The Opportunity in Cockpit Printers |
![]() Boeing 787 Dreamliner Airbus A380 We Are the Exclusive Supplier of Cockpit Printers to New Commercial Aircraft |
![]() C-17 C-130 We Are the Exclusive Supplier of Cockpit Printers to New Military Cargo Aircraft |
![]() Test & Measurement Outlook • Percentage of Current Annual Revenue: 20% • Fiscal Year 2007: Continued growth, propelled by existing contracts |
![]() Meet Astro-Med’s Grass-Telefactor Product Group |
![]() Product Overview EEG Systems PSG Systems System Software & Supplies |
![]() Grass Instruments is the oldest and most respected name in neurological instrumentation • Telefactor is a well-known name in Long Term Epilepsy Monitoring Astro-Med acquired both and merged them, upgrading the resulting product group with proprietary Astro-Med digital technology Brand History: |
![]() Major Grass-Telefactor Opportunities: Sleep (PSG): Rapid growth in treatment of sleep apnea and other sleep disorders Long-Term Epilepsy Monitoring: Product sales to large Research Hospitals |
![]() The Opportunity in Sleep The Opportunity in Sleep |
![]() The Opportunity in Sleep Neurologists and pulmonologists increasingly order PSG (polysomnograph) tests on patients with sleep disorders, often obese people. Aura Wireless PSG Sleep Study System |
![]() The Opportunity in Sleep A Wachovia Securities study indicates the potential growth of sleep studies, finding that just 22% of people who could benefit from sleep studies have received them Aura Wireless PSG Sleep Study System |
![]() Comet EEG System • Brain activity before and after surgery • Especially epilepsy The Opportunity in Long-Term Monitoring |
![]() • Percentage of Current Annual Revenue: 30% • Fiscal Year 2007: Continued growth in Sleep and Long Term Monitoring Grass-Telefactor Outlook: |
![]() Financials Astro-Med, Inc. |
![]() Operating Results Operating Results ($ in Millions) FY 2004 FY 2005 FY 2006* Sales $55.8 $56.0 $59.0 Gross Profit 23.0 23.0 24.5 % 41.2% 41.2% 41.6% Operating Income 3.6 2.6 3.2 % 6.5% 4.6% 5.5% EBITDA 4.9 3.8 4.6 Net Income $3.2 $2.7 (1) $2.5 (2) % 5.8% 4.8% 4.3% EPS $0.60 $0.47 (1) $0.43 (2) (1) Includes tax benefit of $.9 or $0.17 EPS (2) Includes tax benefit of $.4 or $0.06 EPS *Forecast FY2006 |
![]() Test & Measurement 19% - $11.5 Million Grass-Telefactor 30% - $17.8 Million QuickLabel Systems 51% - $29.7 Million Sales by Product Group YE January 31* *Forecast FY2006 Total Sales: $59.0 Million |
![]() QuickLabel Systems $25.3 $28.4 $29.7 Growth by Product Group Growth by Product Group ($ in Millions) YE January 31 FY04 FY05 FY06* *Forecast FY2006 Grass-Telefactor $18.9 $16.5 $17.8 Test & Measurement $11.6 $11.1 $11.5 Totals $55.8 $56.0 $59.0 |
![]() Cash Equivalents and Marketable Securities $13.8 Balance Sheet Balance Sheet ($ in Millions) A/O 10/29/05 Working Capital (excluding cash, cash equivalents, and marketable securities) $16.7 Total Assets $48.0 Total Debt, including current portion -$0- Total Stockholders’ Equity $39.5 |
![]() Total Shares Outstanding 5,313,000 Market Capitalization $62 Million 52 Week Range $8.25 - $13.19 Management Insider Ownership 33% Institutional Ownership 23% Dividend Paid 56 Consecutive Quarters Years of Profitable Operations 26/28 Years Investment Considerations (NASDAQ: ALOT) A/O 12/31/05 |
![]() P/E Ratio* 31x P/B Ratio* 1.6 Book Value per Share** $7.44 Cash per Share** $2.59 Dividend Yield 1.5% *A/O 12/31/05 **A/O 10/29/05 Investment Considerations (NASDAQ: ALOT) |
![]() Stock Performance 3-Year Monthly Comparison As of 12/31/05 |
![]() Investment Considerations (NASDAQ: ALOT) Positioned for Growth & Profitability Proprietary Technology Strong Capital Structure Multiple Million-Dollar Markets New Products Pipeline to support growth Experienced Management with a proven track record Established Global Distribution |
![]() Thank You ALOT ! Visit us at: www.Astro-MedInc.com |